Asset Details
Do you wish to reserve the book?
Malignant effusions and immunogenic tumour-derived exosomes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Malignant effusions and immunogenic tumour-derived exosomes
Do you wish to request the book?
Malignant effusions and immunogenic tumour-derived exosomes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Malignant effusions and immunogenic tumour-derived exosomes
2002
Overview
Exosomes derived from tumours are small vesicles released in vitro by tumour cell lines in culture supematants. To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells.
We isolated exosomes by ultracentrifugation on sucrose and D
2O gradients of 11 malignant effusions. We characterised exosomes with Western blot analyses, immunoelectron microscopy, and in-vitro stimulations of autologous T lymphocytes.
Malignant effusions accumulate high numbers of membrane vesicles that have a mean diameter of 80 nm (SD 30). These vesicles have antigen-presenting molecules (MHC class-I heat-shock proteins), tetraspanins (CD81), and tumour antigens (Her2/Neu, Mart1, TRP, gp100). These criteria, including their morphological characteristics, indicate the similarities between these vesicles and exosomes. Exosomes from patients with melanoma deliver Mart1 tumour antigens to dendritic cells derived from monocytes (MD-DCs) for cross presentation to clones of cytotoxic T lymphocytes specific to Mart1. In seven of nine patients with cancer, lymphocytes specific to the tumour could be efficiently expanded from peripheral blood cells by pulsing autologous MD-DCs with autologous ascitis exosomes. In one patient tested, we successfully expanded a restricted T-cell repertoire, which could not be recovered carcinomatosis nodules.
Exosomes derived from tumours accumulate in ascites from patients with cancer. Ascitis exosomes are a natural and new source of tumour-rejection antigens, opening up new avenues for immunisation against cancers.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adult
/ Aged
/ Antigens, Neoplasm - immunology
/ Antigens, Neoplasm - isolation & purification
/ Cancer
/ Cells
/ Cytoplasmic Vesicles - immunology
/ Dendritic Cells - immunology
/ Female
/ Humans
/ Male
/ Melanoma
/ Neoplasm Proteins - isolation & purification
/ Pleural Effusion, Malignant - cytology
/ Pleural Effusion, Malignant - immunology
/ Tumors
